Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024 08:00 ET | Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
December 05, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
November 27, 2024 08:00 ET | Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024 16:05 ET | Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Revolution Medicines.jpg
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 06, 2024 16:02 ET | Revolution Medicines, Inc.
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...
Revolution Medicines.jpg
Revolution Medicines to Participate in Upcoming Investor Conferences
November 05, 2024 09:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RASolute[71]
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
October 21, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET | Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Dr. Daniel Von Hoff
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET | EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
purple-logo2020.png
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024 07:00 ET | Purple Biotech Ltd.
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...